Features of NF-κB -mediated signal transduction and development of systemic inflammation in patients with diseases of internal organs are determined by microbial factor and individual reactivity of the body (review of own research findings) by Vesnina, L. et al.
Том 19, N 3-4 2015 р.    
 30
28. Савченко Л.Г. Значення метформіну та раміприлу у 
вторинній профілактиці ішемічної хвороби серця і цук-
рового діабету 2 типу / Л.Г. Савченко, А.В. Лавренко, 
Н.Д. Герасименко, М.С. Расін,  І.П. Кайдашев // Вісник 
проблем біології і медицини. – 2014. – Т. 1, Вип. 3(110). 
– С. 304-307. 
29. Сакевич В. Д. Розповсюдженість гаплотипів поліморф-
них генів TLR 2, TLR 4, CLC-10 та їх зв’язок з окремими 
імунологічними показниками у хворих на алергічний 
риніт / В.Д. Сакевич // Проблеми екології і медицини. – 
2013. – Т. 17, № 5-6. – С. 16 –20. 
30. Сакевич В. Д. Поширеність поліморфних алелей 
2258G/A гена TLR2 та їх зв'язок з окремими імунологіч-
ними показниками серед хворих на алергічний риніт / 
В. Д. Сакевич, О. А. Шликова, Н. О. Боброва, І. П. Кай-
дашев // Астма та алергія. – 2013. – № 3. – С. 51-55. 
31. Сакевич В.Д. Розповсюдженість поліморфної алелі 
rs420297 С/Т гену галектину-10 (CLC-10) та її зв'язок з 
окремими імунологічними показниками серед хворих 
на алергічний риніт / Сакевич В.Д., Шликова О.А., Із-
майлова О.В.  // Імунологія та алергологія: Наука і 
практика. – 2013. - № 3. – С. 8-13. 
32. Сакевич В.Д. Клінічний  перебіг та особливості стану 
клітинного й гуморального імунітету у хворих на алергі-
чний риніт / В.Д. Сакевич, Н.Л. Куценко, М.В. Микитюк, 
І.П. Кайдашев // Лікарська справа. – 2014. – № 1-2. – С. 
15-20. 
33. Сакевич В.Д. Особливості імунного статусу хворих на 
алергічний риніт у залежності від поліморфізму генів 
TLR 2, 4 та галектину-10 / В.Д.  Сакевич, О.А. Шликова, 
І.П. Кайдашев // Проблеми екології та медицини. – 
2014. – Т. 18, № 3-4. – С. 34-39 (англ. 39-43). 
34. Скочко О.В. Роль некоторых пародонтопатогенных 
микроорганизмов и Asp299Gly полиморфизма гена 
TLR4 в патогенезе атеросклероза / О.В. Скочко, Н.А. 
Боброва, О.В. Измайлова, И.П. Кайдашев // Журнал 
микробиологии, эпидемиологии и иммунобиологии. – 
2011. - № 5.- С. 83-86. 
35. Скочко О. В. Количественный анализ отдельных групп 
микроорганизмов выделенных из атеросклеротически 
измененных коронарных артерий пациентов в зависи-
мости от Asp299Gly полиморфизма гена TLR4 / О. В. 
Скочко, Л. Э. Веснина, Н. А. Боброва, О.А.  Шлыкова, 
Т.В. Мамонтова, О.В. Измайлова, И.П. Кайдашев // Лі-
карська справа. – 2012. - № 3-4. – С. 82-86. 
36. Скочко О.В. Аналіз окремих груп мікроорганізмів, виді-
лених із атеросклеротично змінених коронарних арте-
рій хворих, в залежності від Asp299Gly поліморфізму 
гена TLR4 / О.В. Скочко, Л.Е. Весніна, Н.О. Боброва, 
О.А. Шликова, Т.В. Мамонтова, О.В. Ізмайлова, І.П. 
Кайдашев // Проблеми екології і медицини. – 2013. – Т. 
17, № 3-4. – С. 56 –58. 
37. Скочко О.В. Взаимосвязь заболеваний пародонта с 
факторами риска развития ишемической болезни сер-
дца / О.В. Скочко, Т.В. Мамонтова, Л.Е. Весніна, І.П. 
Кайдашев // Український кардіологічний журнал. – 
2015. – № 2. – C. 87 – 94. 
 
 
 
ENGLISH VERSION: FEATURES OF NF-KB-MEDIATED SIGNAL 
TRANSDUCTION AND DEVELOPMENT OF SYSTEMIC INFLAMMATION 
IN PATIENTS WITH DISEASES OF INTERNAL ORGANS ARE  
DETERMINED BY MICROBIAL FACTOR AND INDIVIDUAL  
REACTIVITY OF THE BODY 
(REVIEW OF OWN RESEARCH FINDINGS)* 
L.E. Vesnina, O.V. Izmailova, O.A. Shlykova, I.P. Kaidashev 
Higher State Educational Establishment of Ukraine "Ukrainian Medical Stomatological Academy", Poltava 
The paper identifies the etiological significance of periodontopathogenic microflora in the initiation of low-intensity sys-
temic inflammation, which together with insulin resistance and lipid metabolism determines the development of athero-
sclerosis and coronary heart disease. On the basis of obtained data, the paper substantiates the concept of permanent 
activation of transcription factor NF-κB as the molecular foundation of systemic inflammation and other components that 
form the metabolic syndrome. The role of polymorphic variants of TLR 2,4,3,6 genes in shaping the individual reactivity 
of patients has been determined. The participation of genetic variation of receptor and structural proteins in determining 
the individual sensitivity, clinical course and complications of infectious diseases – hepatitis C, influenza, and EBV-viral 
infection has been justified. The up-to-date role of fundamental processes of innate and acquired immunity in the 
pathogenesis of atopic dermatitis, allergic rhinitis and bronchial asthma has been demonstrated.  The efficiency of devel-
oped methods of therapy with additional inclusion of metformin and pioglitazone has been demonstrated, the application 
of pharmacogenetic approach to treatment has been substantiated. The obtained results will contribute to the formation 
of a systematic approach to the development and use of new technologies for prevention and effective pharmacogenetic 
treatment of diseases which are based on chronic inflammation. 
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I. The role of periodontal pathogenic microflora in 
the initiation of systemic inflammation, etiology 
and pathogenesis of atherosclerosis  
Recent studies have attracted the attention of scien-
tists to the specific source of systemic infection. It has 
been found that under certain conditions a change in bio-
cenosis occurs and oral microflora changes its range to-
ward the high pathogenicity, becoming not only the cause 
of inflammatory diseases of the dentition, but of inflam-
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matory diseases of other organs and systems as well, 
which is an extremely negative phenomenon [26]. 
Identifying the leading etiopathogenetic factors of the 
most common cardiovascular diseases such as coronary 
heart disease (CHD), myocardial infarction, angina pecto-
ris, hypertension, peripheral vascular disease, stroke, 
has shown that among the entire range of factors, 
chronic infection and inflammation are the key ones [8, 
9]. The presence of excessive quantities of periodontopa-
thogenetic microflora in various inflammatory diseases of 
the mouth was the basis of assumption that in the dis-
eases of dentition, the pathogenetic mechanisms of 
which involve the expressed immunological components, 
changes in organs or tissues of the cardiovascular sys-
tem are observed. 
Further research confirmed that not only periodonto-
pathogenetic microflora is a key source which performs 
the triggering role in the development of local and sys-
temic chronic inflammation, but also acts as an inde-
pendent risk factor for CHD. 
During examination of CHD patients with inflamma-
tory diseases of the dentition, a number of risk factors 
were identified, including male sex (63.5%), hereditary 
nature of coronary heart disease (41.3%) and arterial hy-
pertension – AH (76%), AH in anamnesis (57%), over-
weight and obesity (85.7%), diabetes mellitus type 2 
(31.7%), inflammatory diseases of the dentition (3.2-
84.1%), smoking (49.2 %), psycho-emotional stress 
(100%), systemic inflammation, impaired glucose toler-
ance (49.2%), dyslipidemia, microalbuminuria (23.8%). 
The presence of inflammatory pathology of the dentition 
(mono- or comorbidity) was observed in 95.3% of pa-
tients, median caries in 44.4%, chronic periodontitis in 
36.5%, local periodontal disease in 84.1%, chronic gen-
eralized periodontitis in 3.2% of patients. 
The results confirm that along with the already known 
risk factors (obesity, dyslipidemia, hypertension, carbo-
hydrate metabolism) in patients with CHD the proportion 
of inflammatory diseases of the dentition is 95.2%. The 
established relationship between periodontal diseases 
and risk factors of CHD according to the correlation 
analysis influences the development of atherosclerotic 
process. 
The results show that disorders of metabolic proc-
esses that occur in CHD (carbohydrate metabolism dis-
turbance, dyslipidemia, systemic inflammation) and sen-
sitivity of periodontium and its structures to the factors 
that form proatherogenic range of metabolic disorders 
are the basis for a close relationship with the condition of 
oral microflora and justify the risk of the pathology of sys-
temic inflammatory component, including cardiovascular 
disease [37]. 
Investigation of coronary artery samples obtained at 
autopsy of patients who died of coronary artery disease 
and healthy people showed the presence of periodonto-
pathogenetic microorganisms in atherosclerotic plaques 
of 83.9%. In determining the DNA of pathogens by poly-
merase chain reaction, in 51.6% of cases 2 or more mi-
croorganisms were manifested, among them most often 
– Porphyromonas gingivalis (64.5%), Treponema denti-
cola (41.9%), Actinobacillus actinomycetemcomitans 
(32.3%), and less frequently – Bacteroides forsythus and 
Prevotella intermedia (12.9 and 6.5% respectively). It 
should be noted that only in 11.1% of coronary vessels 
samples, in plaques of which microorganisms were pre-
sent, they were identified in intact tissues [34, 36]. 
The obtained data required to determine the maxi-
mum number of microbial flora and quantification of cer-
tain types of pathogenic and opportunistic microorgan-
isms in atherosclerotic lesions of vessels, assessment of 
microcytosis, level of microflora imbalance which led to 
the development of the method for determining the micro-
flora in atherosclerotic lesions of vessels with the release 
of microbial DNA followed by amplification and detection 
of the results [35]. 
Investigating the presence of different types of paro-
dontopathogenic microorganisms in the blood vessels in 
CHD enabled us to come to the conclusion that their 
DNA detection rate reaches 100% in tissue samples of 
atherosclerotic plaques in coronary arteries. Analysis of 
own data and the data of other authors allowed us to 
identify the main mechanisms initiated by the impact of 
long-persistent oral microbiota in the development of 
atherosclerosis: the direct one – bacterial penetration 
with the bloodstream into the cells of vascular endothe-
lium; and / or indirect one – bacterial stimulation of the 
production of mediators with atherogenic and pro-
inflammatory systemic effects. Both ways cause the de-
velopment of main manifestations of atherosclerosis, 
such as endothelial dysfunction, systemic inflammation, 
platelet aggregation and the formation of atheromatous 
plaques and require the modern approaches to preven-
tion and treatment of diseases of the cardiovascular sys-
tem, taking into account the mechanisms of influence of 
the bacterial infection in the development of atheroscle-
rosis [26]. 
II. Genetic variability as a factor of influence on 
immune reactivity of the body to microbial factors 
Recent studies show that individual reactivity and 
susceptibility to microbial infection and viral pathogens to 
a large extent depends on the genetic processes of im-
plementation of hereditary information and epigenetic in-
fluences. 
Taking into account the presence of parodontopatho-
genic microorganisms in atherosclerotic plaques and the 
surrounding tissues of patients who died of ischemic 
heart disease, there has been raised a question of possi-
ble connection of atherosclerosis and genetic factors, in 
particular the polymorphic variants of genes that mediate 
the processes of immune response, such as genes of 
Toll-like receptors (TLR). As is known, TLRs belong to 
the pattern-recognizing group of receptors. In particular, 
TLR2 recognizes peptidoglycan – the main structural 
component of the cell wall of gram-positive bacteria and 
microbial lipopeptides of gram-positive and gram-
negative bacteria. TLR4 interacts with lipopolyssacharide 
(LPS) and lipoteichoic acid which is the main component 
of cell membranes of bacterial cells. 
The study of coronary artery samples of patients who 
died of ischemic heart disease and those who died due to 
other causes, not related to coronary artery disease, was 
conducted. Asp299Gly polymorphic area of TLR4 gene 
was amplified using specific primers. Studies have shown 
that in patients who died of ischemic heart disease, the 
polymorphic allele of the gene TLR4 G 896 was signifi-
cantly more common (p = 0.04), OR 2.92 (1.15-7.41). 
Moreover, it was found that the presence of the poly-
morphic allele G of TLR4 gene in individual genotype de-
termines the increased contamination of the plaque tis-
sue by representatives of certain types of odontogenic 
pathogens: Lactobacillus spp., Enterobacterium spp., 
Sneathia spp. / Leptotrihia spp. / Fusobacterium spp., 
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Mobiluncus spp. / Corynebacterium spp., Peptostrepto-
coccus spp. The results showed the participation of these 
groups of microorganisms in the pathogenesis of athero-
sclerosis, and identified the etiologic role of polymorphic 
variant of TLR4 gene in increased microbial contamina-
tion of tissues of coronary arteries [36]. 
It was found that in the group of patients with athero-
sclerotically modified coronary vessels, there were 15 
individuals with genotype AA (Asp299Asp) of TLR4gene, 
3 – with genotype AG and 2 – with genotype GG. Geno-
types AG and GG were combined into one group as the 
carriers of mutant allele G. The carriers of allele G (AG 
and GG) had a significantly higher content of microbial 
DNA of Lactobacillus spp. 4.20±0.62 as against 
3.01±0.14 in carriers of allele A (AA) (p<0.05), Entero-
bacterium spp. – 4.68±0.87 as against 3.09 ± 0.17 
(p<0.05), Sneatia spp. / Leptotrichia spp. / Fusobacterium 
spp. – 3.47±0.60 as against 1.78±0.16 (p<0.05), Mo-
biluncus spp. / Corynebacterium spp. – 3.06±0.46 as 
against 2.18 ± 0.10 (p<0.05), Peptostreptococcus spp. – 
3.08±0.67 as against 2.00±0.11 (p <0.05) [35]. 
It was confirmed that investigated odontogenic patho-
gens play an important role in the pathogenesis of 
atherosclerotic lesions of the coronary vessels and the 
development of coronary artery disease. Important is the 
role of TLR4 gene polymorphism, when individuals with 
299Gly allele have a chance of contracting CHD by 2.92 
times more likely than those with the presence of 299Asp 
allele [34]. 
The data prompted us to pay attention to the relation-
ship of microbial genetic factors with the change of ge-
netic status of the immune system elements already in 
other pathological conditions. 
Taking into account the possible involvement of TLR 
in the immunopathogenesis mechanisms of urogenital 
infections, we studied the population prevalence of SNP 
of TLR2 Arg753Gln genes with the replacement of G to A 
in position 2258 (rs5743708) and TLR4 Asp299Gly with 
the replacement of A for G in position 1187 (rs4986790), 
as well as Thr399Ile with the replacement of C to T in po-
sition 1487 (rs4986791) among the apparently healthy 
individuals of Poltava population and among patients with 
common urogenital diseases. We clarified the role of 
functional polymorphism in genes that encode TLR in the 
development of susceptibility to infection with the most 
common causative agents of urogenital infections [5]. 
Genotyping of the studied groups as to the polymor-
phisms of TLR2 Arg753Gln gene and TLR4 Asp299Gly 
gene, Thr399Ile was conducted using PCR and subse-
quent restriction analysis. Statistically significant associa-
tion between A allele of TLR2 gene (p = 0.0018) and G 
allele of TLR4 gene (p = 0.085) with the presence of uro-
genital diseases was determined. 
Analysis of the obtained data led us to the assump-
tion of a reliable association between the presence of 
mutant alleles of TLR2 Arg753Gln and TLR4 Asp299Gly 
genes and increased risk of contracting common urogeni-
tal infections, in particular whose causative agents are 
Chlamydia trachomatis, Ureaplasma urealyticum, My-
coplasma genitalium, Gardnerella vaginalis, Neisseria 
gonorrhoeae, Trichomonas vaginalis. 
The search for pathogenetic factors that would sub-
stantiate the mechanism of increased risk of infection di-
rected the attention to the study of synthesis of pro-
inflammatory cytokines (interleukin-6 (IL-6), tumor necro-
sis factor-α (TNF-α)) and anti-inflammatory cytokines – 
IL-10 by mononuclear cells of peripheral blood (MCPB) in 
patients with various 896A/G polymorphic variants of 
TLR4 gene (rs4986790) under TLR ligands (LPS and 
zymosan) [6]. 
The results displayed the insufficient production of in-
flammatory cytokines IL-6 and TNF-α. It was concluded 
that the reduced ability to produce inflammatory cyto-
kines (IL-6 and TNF-α) in response to LPS and zymosan 
in patients with existing 896G allele of TLR4 gene 
(rs4986790) can cause susceptibility to infection with 
gram-negative (in particular, urogenital) pathogens and 
cause immunodeficient condition that is of hereditary na-
ture, involving at least the functional polymorphism of 
TLR4 (rs4986790). 
An important step was the study of the mechanisms 
of immunoregulation in patients with atopic bronchial 
asthma (ABA) depending on the polymorphism 2258G/A 
of TLR-2 gene (rs5743708) [24]. The examination of rep-
resentatives of patients with ABA from Poltava population 
showed that single-nucleotide polymorphism 2258G/A of 
TLR2 gene is revealed in them more often than in healthy 
individuals. 
It was determined that there is a clear dependence of 
patients’ immune status on TLR2 genotype. In patients 
with compensated course of ABA who carry homozygous 
allele G, a wide range of positive correlation relationships 
against the background of increased IL-4 level is formed. 
Heterozygous variant of TLR2 gene in patients with com-
pensated ABA promotes the imbalance of immune sys-
tem with activation of IL-10 production, a significant de-
crease in the number of correlation relationships of im-
mune-dependent structures and direct linear relations 
between natural regulatory T cells and T-helper cells and 
lymphocytes. 
It was suggested that controllability of ABA course 
under conditions of heterozygous TLR-2 genetic appara-
tus and certain decrease in activity of innate immunity, is 
possible due to the direct interaction between regulatory 
T cells with other types of lymphocytes which creates a 
balance between effector and regulatory mechanisms of 
the immune response. The increased level of inducible 
IL-10 of T-reg cells in ABA allowed to confirm their impor-
tant role in the diagnosis and promising outlook in the 
treatment of atopic states, especially in patients with 
functional genetic disorders. 
Taking into account the multifactorial nature of ABA 
as pathology, gene polymorphism of Clara cells protein 
(A38G), with specific weight of 16 kDa (SS16) in adults of 
Poltava population, the features of clinical course of ABA 
and level of total IgE depending on changes in the ge-
nome [25] were investigated. 
It was determined that polymorphic variant 38G of 
CC16 gene is significantly more common in patients with 
ABA than the group of population control (p = 0.019), and 
the level of total IgE is statistically and significantly higher 
in patients with heterozygous (AG) and homozygous 
(GG) variant of CC16 gene. The carriership of polymor-
phic allele 38G of CC16 gene influenced the ABA clinical 
manifestations: fungal sensitization, atopic dermatitis and 
tuberculosis in anamnesis were observed in patients; it 
necessitated more frequent administration of glucocorti-
coids. 
An important step was the cumulative study of 
2258G/A polymorphisms of TLR2 gene (rs5743708) and 
896A/G of TLR4 gene (rs4986791), protein gene of Clara 
cells (A38G), with specific weight of 16 kDa (CC16) in 
adults of Poltava population and defining the features of 
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the immune status and clinical course of bronchial 
asthma depending on changes in the genome [23]. 
The results show that in patients with BA it is more 
likely to identify TLR2 gene (p = 0.04) against back-
ground of GA genotype (11.1%), in patients who are car-
riers of the mutant allele A of TLR2 gene in anamnesis 
pneumonia was observed more frequently (p = 0.046) 
and there were signs of candidiasis (p = 0.034) as com-
pared with patients without polymorphism. 
In the study of TLR 4 gene polymorphism it was found 
that AG genotype is statistically more likely (p = 0.04) to 
be found in the group with BA (15.6%) than in the control 
group. In patients with 896A/G polymorphisms of TLR4 
gene the disease initiated in childhood (p = 0.03), food 
factors were detected in the sensitization spectrum (p = 
0.02) and there were signs of other allergic pathologies 
(p = 0.045). 
The results gave us the opportunity to affirm the im-
portance of the study of 896A/G polymorphisms of TLR4 
gene and 2258G/A of TLR2 gene, A38G gene of CC16 
gene for the diagnosis, prevention and treatment of BA. 
The latest data concerning the important role of TLR2 
gene as a candidate gene in the development of asthma 
in children, possible connection of TLR2 gene polymor-
phism with allergic asthma contributed to determining the 
presence of relationship between TLR2 Arg753Gln poly-
morphism (NP_003255.2) and increased synthesis of 
specific E immunoglobulins in patients with allergic dis-
eases [4]. 
It was confirmed that TLR2 Arg753Gln polymorphism 
is associated with increased levels of sIgE production in 
patients with allergic diseases. TLR2 polymorphism can 
also affect numerous functional consequences of TLR2 
activation related to signalling pathways of NF-κB and 
MAPK, including sIgE production. The available results 
allowed to consider this as polymorphism as an addi-
tional predictive index used for genetic research of aller-
gic diseases. 
Similar results were also obtained by us in the study 
of association of Toll-like receptor 4 polymorphism 
(NP_612564.1) with increased production of specific IgE 
in patients with allergic diseases [15]. It was determined 
that Asp299Gly polymorphism of TLR4 gene is associ-
ated with increased production of sIgE in patients with 
allergic diseases. 
Overall, the research results not only demonstrate the 
relationship of TLR2 (rs5743708) and TLR4 (rs4986790) 
polymorphisms with increased production of specific IgE 
in patients with allergic diseases, but also allows to use 
these single nucleotide replacements as additional prog-
nostic features of individual susceptibility to these dis-
eases [14]. 
The important property of TLR consists not only in the 
fact that it is a central link of the innate immune in antivi-
ral immune response, but also in their ability to interact 
with the structures of viruses – proteins, glucoproteins, 
lipoproteins, RNA and DNA which significantly contrib-
uted to further study. Respiratory viruses – influenza, pa-
rainfluenza, adenoviruses, rhinoviruses and respiratory 
syncytial virus are the most common causes of acute 
respiratory viral infections (ARI) in children. Viral infection 
is one of non-specific factors that reinforce the effect of 
causal factors in atopic dermatitis, and is the most signifi-
cant risk factor for atopic syndrome. 
Therefore, at the next stage the association of 
896A/G polymorphism of TLR4 gene with features of 
clinical course in atopic dermatitis in children with a ten-
dency to frequent SARS was studied [21]. 
Analysis of the obtained data showed that in the 
group of children with atopic dermatitis with susceptibility 
to frequent SARS the mutated 896G allele of TLR4 gene 
is detected significantly more frequently (9.3%) as com-
pared with the control group (χ2 = 4.33; OR = 5.06 ; CI = 
1.28-20.08, p = 0.038). The presence of mutant 896G 
alleles of TLR4 gene was associated with severe course 
of the disease (p=0.0485); concomitant adenoid vegeta-
tions combined with allergic rhinitis and / or BA 
(p=0.0248) and allergic rhinitis (p = 0.0053); polyvalent 
allergy to 4 types of allergens (p=0.0485). It is concluded 
that the presence of 896A/G polymorphism of TLR4 gene 
is essential in determining the severity of atopic dermati-
tis and development of complications. 
Detecting the presence of 1196C/T polymorphisms of 
TLR4 gene (rs4986791) and 2258G/A of TLR2 gene 
(rs5743708) in children with atopic dermatitis and possi-
ble association of these polymorphisms with increased 
susceptibility to infection did not produce credible results 
[22]. 
The research determined that 2258G/A polymorphism 
of TLR2 gene (rs5743708) is important in determining the 
course of allergic rhinitis (AR), confirming the pathoge-
netic link between innate and adaptive immunity in AR 
[30.32]. 
In particular, the significant difference between the 
groups of patients with AR with the presence of mutant 
2258G/A allele of TLR2 gene and homozygous carriers 
of the “wild” alleles in terms of CD4+ (U (n = 42; n = 3) = 
12.00; p = 0.020) was revealed. In patients with AR, mu-
tant 2258G/A allele of TLR2 gene, the level lymphocytes 
was significantly higher than in homozygous carriers of 
the “wild” allele (U (n = 42; n = 3) = 11.50; p = 0.019) with 
AR. 
A broader study embraced the determining of the role 
of genes polymorphisms, not only 2258G/A of TLR2 gene 
(rs5743708), and 896A/G of TLR4 gene (rs4986790) and 
galectin-10 gene (rs420297 C/T)) in the pathogenesis of 
AR, in order to improve knowledge of immunological 
mechanisms of this disease [29, 33]. 
The study of allergic anamnesis revealed that in 76% 
of cases AR in patients is largely of hereditary nature on 
the mother’s side (36%), it mostly begins in childhood 
and adolescence (88%) and in 44% is accompanied by 
other allergic diseases. 89% of patients with AR had 
positive skin tests for domestic, epidermal, pollen, food 
and fungal allergens, 82% had polyvalent sensitization to 
two or more groups of allergens. 
In the study of the immune status of patients with AR 
it was found that in 15% of patients eosinophilia, in-
creased average levels of total immunoglobulin E, the 
relative increase in the number of CD4+CD25+Foxp3+ 
Treg cells with reduction of IL-10 and increased IL-4 were 
observed. 
In the group of patients with AR, prevalence of TLR2 
gene polymorphism (rs5743708) was established: GG 
genotype was 93.3%, genotype GA – 6.6%, genotype AA 
was not observed. 
The spread of TLR4 gene polymorphism 
(Asp299Gly): AA genotype was 92.3%, genotype AG – 
7.7%, GG genotype was not observed. The significant 
difference between the frequencies of genotypes in the 
control group and patients with AR (p = 0.03) was de-
tected. In patients with AR, G allele carriers for 896A/G 
polymorphism of TLR4 gene, the atopic pathology was 
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detected: concomitant BA (p = 0.0003), concomitant AD 
(0.0031) and BA in combination with AD (p = 0.0005). 
The spread of rs420297 polymorphism of galectin-10 
gene among persons living in Poltava region is CC-76%; 
CT-22%; TT-2%. The significant difference between the 
frequencies of genotypes in the control group and pa-
tients with AR (p = 0.04) and the frequency of T allele of 
CLC-10 in the group of patients was observed: by 30% 
as compared with the control group, 13% (χ2 = 6.42; p = 
0.011), rs420297 polymorphism of CLC-10 gene was 
significantly more common in the group of patients with 
RA. The development and course of allergic rhinitis is as-
sociated with rs420297 polymorphism of CLC-10 gene (a 
year-round form of AR occurs significantly more often in 
patients with AR mutant allele CLC-10 (p = 0.0001)). 
Moreover, the significant association between the 
presence of polymorphic alleles of CLC-10 gene and 
CD4+ levels (p=0.014), CD4+CD25+ (p=0.012) was re-
vealed; in the group of homozygous carriers of polymor-
phic allele T and allele C of CLC-10 gene the significant 
association between the presence of polymorphic allele 
of CLC-10 gene and CD4+CD25+Foxp3+ levels (p=0.037), 
CD4 + (p = 0.014) was established. It was determined 
that individuals who have polymorphic allele of CLC-10 
gene have significantly higher levels of IgE (p = 0.013) 
and IL-4 (p = 0.004) and lower level of IL10 (p = 0.038) 
[31]. 
One of the most common bacterial infections is 
caused by Helicobacter pylori (H.pylori), promoting the 
development of gastric diseases, immune and inflamma-
tory responses. However, the severity of inflammation 
may depend on the interaction of certain factors such as 
the virulence of pathogen, reactivity, external factors. 
Among etiopathogenetical factors, genetic influences 
play a certain role. 
The features of H. pylori infection in children with 
ASP299GLY polymorphism of TLR4 gene were investi-
gated [1]. 
In children with Asp/Gly SNP Asp299Gly genotype of 
TLR4 gene the decrease in expression of TLR4 in bioptic 
material of gastric mucosa, and the decrease in water-
soluble sCD14 level while maintaining severe inflamma-
tory changes in the mucosa were observed. It was de-
termined that in children with chronic gastroduodenal in-
flammatory diseases Asp/Gly SNP Asp299Gly genotype 
of TLR4 gene is observed significantly more often than in 
healthy children. It is concluded that the presence of 
Asp/Gly SNP Asp299Gly genotype of TLR4 gene in chil-
dren causes susceptibility to infection with H. pylori. 
Scientific achievements of corporate authors suggest 
that the clinical course of HIV infection in patients with 
Asp299Gly polymorphism of TLR4 gene may have cer-
tain features that require further research in this area 
[13]. 
It was determined that in HIV-infected patients 
Asp299Gly polymorphism of TLR4 gene is observed sig-
nificantly more frequently than in healthy subjects (12.0% 
and 2.1% respectively, p <0.005). 
Comparisons of clinical and immunological character-
istics of HIV patients according to the presence of the 
Asp299Gly polymorphism of TLR4 gene suggest that in 
HIV-infected patients with existing polymorphism there 
are features of clinical course and immune status that 
should be considered during examination and treatment. 
In particular, the HIV heterozygous genotype (AG) of 
TLR4 gene is associated with increased risk of mixed pa-
thologies of viral, bacterial and parasitic etiology. The de-
velopment of opportunistic infections in the presence of 
Asp299Gly polymorphism of TLR4 gene is implemented 
at a higher level of CD4 lymphocytes, which raises the 
question as to the appropriateness to reconsider the pre-
scription of antiretroviral therapy and chemoprophylaxis 
of opportunistic infections. 
Equally important medical problem is the search for 
etiopathogenic markers of such a widespread and unpre-
dictable in terms of clinical course viral disease as influ-
enza. The current stage of science defines the study of 
genetic factors associated with the development of influ-
enza and its complications as the main focus of research. 
The prevalence and prognostic significance of 
Arg753Gln polymorphisms of TLR2 gene, Leu412Phe of 
TLR3gene, Asp299Gly of TLR4 gene in influenza were 
investigated [3]. 
Studies have shown that the frequency of heterozy-
gous Asp/Gly genotype of TLR4 in patients with influenza 
is 12.69%; influenza-associated pneumonia – 14.28%, 
which exceeds the population control by 3.8-4.3 times 
(3.33% p <0.005). It was determined that the homozy-
gous Phe/Phe genotype of TLR3 in patients with influ-
enza-associated pneumonia is in 18.37%, which is more 
than in patients without influenza complications (4.76%, p 
= 0.02) and healthy individuals (5.0 %, p = 0.03). 
The combination of mutant genotypes of TLR2, TLR3 
and TLR4 was defined only in cases of influenza and in-
fluenza-associated pneumonia with the rate of 11.11-
14.28% (p <0.005). 
It was concluded that the presence of polymor-
phomodified genotypes of TLR3 and TLR4, their combi-
nations with TLR2 allows predicting the development of 
influenza and influenza-associated pneumonia. The risk 
of influenza in terms of odds ratio is 4.2 times higher than 
in people with Asp/Gly genotype of TLR4 gene, by 15 – 
in combination of mutant genotypes of TLR2, TLR3 and 
TLR4, and the risk of influenza-associated pneumonia is 
by 4.5 times higher in patients with homozygous mutant 
genotype Phe/Phe of TLR3. 
III. The nuclear transcription factor κB from  
the standpoint of syntropy of infectious  
and non-infectious pathologies 
Studies of recent decades have shown that nuclear 
transcription factor κB is in the centre of many pathologi-
cal conditions. Its signalling pathway of receives signals 
from many stimuli of both infectious and non-infectious 
nature, it plays the role of the leading proinflammatory 
way. 
A number of published papers and the results of our 
own research allowed to formulate the concept of long-
term and low intensity activation of NF-κB as a possible 
molecular basis for syntropy of internal diseases which is 
based on evolutionary aspect and action conditions of 
advanced modern factors [7, 12]. 
According to the concept of syntropy and syntropic 
pathology, the most common diseases and pathological 
conditions such as insulin resistance, chronic systemic 
inflammation, type 2 diabetes, hepatocellular failure, 
atherosclerosis, osteoporosis, bronchial asthma, chronic 
obstructive pulmonary disease, Alzheimer's and Parkin-
son's have common pathogenetic mechanisms, or sepa-
rate elements of these mechanisms [9]. 
In favour of the concept are the positive results of tar-
geted therapy with agents that affect the activity of NF-κB 
and the expression of its target genes (IL-1β, IL-6, TNF-
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α), influence the process of insulin resistance (biguanide, 
activators of PPAR- γ). 
In particular, the data were obtained indicating the 
decrease in NF-κB activity, concentrations of proinflam-
matory cytokines and CRP using biguanides (metformin) 
and PPAR-γ activators (pioglitazone) [2, 16, 18, 19]. 
It should be noted that the results were obtained con-
firming that genetic polymorphism of proteins that are as-
sociated with a cascade of NF-κB-mediated reactions – 
PPAR-γ2, angiotensin receptor II type 1, TLR 2 and 4 – 
may influence the development of internal diseases [8], 
thus forming the foundation for further research and bind 
in certain pathogenic cascade the following elements: 
pathogen – perceiving (receptor) cell apparatus – interac-
tion with signalling NFκB cascades – implementation of 
the inflammatory response. 
IV. Preconditioning of anti-inflammatory pathway 
of NF-κB as a mechanism to influence syntropy 
Our data suggest that polymorphisms of genes that 
provide immune response of the body underlie the ge-
netic susceptibility to immune-mediated diseases and de-
termine the high susceptibility to infectious and allergic 
diseases. According to the concept of long-term and low-
intensity activation of NF-κB as a possible molecular ba-
sis for syntropy of internal diseases, we conducted the 
research related to the mechanisms of preconditioning of 
proinflammatory NF-κB pathway. 
 The strategic target for therapy of a number of dis-
eases in which the NF-κB signalling cascade is involved 
is the systemic inflammatory response with hyperlipide-
mia and insulin resistance related to it. Thiazolidin-
ediones – receptor agonists that activate proliferation of 
peroxisome-γ (PPAR-γ) – are successfully used in mod-
ern therapy for regulation of these processes.  
Adding pioglitazone to the standard therapy for pa-
tients with coronary heart disease and metabolic syn-
drome resulted in lower concentrations of triglycerides, b-
lipoproteins, total cholesterol and total lipids in serum, not 
only in comparison with the original parameters in these 
patients before treatment, but with the parameters of the 
comparison group after standard therapy [2]. 
The obtained data confirm that the prescription of 
pioglitazone effectively influences the processes associ-
ated with insulin resistance, helps to significantly reduce 
the concentration of immunoreactive insulin and reliably – 
the blood glucose, indicating a decrease in the severity of 
insulin resistance. 
The use of pioglitazone in the treatment of patients 
with coronary heart disease and metabolic syndrome 
lowers systemic inflammation and lipid metabolism and 
significantly reduces insulin resistance. The inclusion of 
pioglitazone into the therapy in patients with complex 
coronary artery disease (exertional angina) against the 
background of metabolic syndrome does not increase 
cardiovascular risk and improves the clinical course of 
the disease, increases the effectiveness of standard 
treatment of coronary artery disease. The study allows us 
to recommend the inclusion of pioglitazone therapy in the 
comprehensive therapy of CHD and metabolic syndrome. 
Another drug that has anti-inflammatory and insu-
linosensitizing activity is metformin. The assessment of 
its effect on NF-κB-signalling pathway in patients with 
coronary artery disease against the background of meta-
bolic syndrome was conducted. The inclusion of monthly 
course of metformin into the comprehensive therapy in 
CHD reduced production of proinflammatory cytokines IL-
1β, IL-6, IL-8 and TNF-α, as well as reduced the level of 
C-peptide concentration in serum [18]. 
It was concluded that the inclusion of metformin in 
comprehensive therapy of CHD with metabolic syndrome 
prevents activation of NF-κB under the action of endoge-
nous inflammatory cytokines. 
Taking into account the obtained results, the data of 
scientific literature were considered as to the molecular 
mechanisms of metformin and pioglitazone and role of 
nuclear transcription factors: NF-κB and PPAR-γ. 
The results of own research show a significant reduc-
tion of inflammatory cytokines when metformin and piogli-
tazone are included into in the comprehensive therapy of 
coronary artery disease in patients with metabolic syn-
drome. In older women it took place both in the presence 
of abdominal obesity, and without it, indicating the crucial 
role of systemic inflammation and insulin resistance in 
the pathogenesis of metabolic syndrome. 
It seems probable that the overall action mechanism 
of these drugs, despite their belonging to groups with dif-
ferent action mechanisms, is their influence on the sup-
pression of chronic systemic inflammation of low inten-
sity, which is the basis of all chronic human pathologies. 
The data confirm that it is appropriate to introduce deter-
mining the markers of inflammation and insulin resistance 
into the panel of necessary studies in order to establish 
the risk tendency of modern man to the development of 
the most common diseases, such as cardiovascular dis-
ease, type 2 diabetes, chronic obstructive pulmonary dis-
eases, neoplastic diseases and others. 
It is an already admitted idea that insulin resistance is 
the pathogenetic basis for metabolic syndrome. It is as-
sumed (Egger G., 2011) that hypertrophied metabolically 
active adipose tissue produces inflammatory cytokines 
and angiotensinogen which renders blockade of intracel-
lular signalling pathways of insulin with the development 
of insulin resistance, activation of the renin-angiotensin 
system with the development of hypertension, endothelial 
dysfunction, hyperlipidemia and inflammatory damage to 
the artery wall with the development of atherosclerosis.  
The conclusion was made about the need to shift the 
focus to the studies of the molecular mechanisms of the 
immune system activation, suggesting as to insulin resis-
tance the etiologic role of chronic systemic inflammation. 
Recognition of chronic systemic inflammation as the etio-
logical factor for insulin resistance, whether this be 
chronic systemic inflammation either acquired or geneti-
cally determined, can, in our opinion, ultimately provide 
metabolic syndrome with the status of a nosology instead 
of a syndrome (the assembly of just pathogenetically re-
lated symptoms that do not have common etiology) and, 
even more, not “the community of individual, not related 
risk factors for cardiovascular disease”. In its turn, the 
study of external, genetic and molecular factors of 
chronic systemic inflammation and insulin resistance will 
open new pathways for prevention and treatment of hu-
man chronic diseases [17]. 
In subsequent studies it was shown that the combina-
tion of metformin and ramipril (1000 mg and 5 mg per 
day respectively) in the treatment of metabolic syndrome 
within 6 months leads to improved clinical course of 
coronary artery disease, reducing the number and dura-
tion of painful heart attacks, reduced functional class of 
angina, decrease of chronic heart failure, normalization of 
blood pressure and reduction of abdominal obesity. 
This effect can be seen as prevention of type 2 diabe-
tes and its cardiovascular complications. The combina-
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tion of metformin and ramipril in treatment of metabolic 
syndrome is an effective and safe treatment option [27, 
28]. 
In order to confirm the obtained data, the effective-
ness of the medium-term inclusion of metformin into the 
comprehensive therapy of patients with type 2 diabetes 
combined with coronary artery disease was studied in 
order to justify the rational timing and dose of the medica-
tion. In 52 patients suffering from type 2 diabetes and 
coronary artery disease the influence of metformin inclu-
sion (1 g daily) into the comprehensive therapy for 3 
month was studied as compared to the primary level and 
the results obtained after 1 month of treatment. 
The results showed that after 3 months, the tendency 
to clinical parameters improvement is maintained, reduc-
ing the functional class of angina, the severity of heart 
failure, blood pressure, and retaining the achieved reduc-
tion in body mass index are observed. There is further 
improvement in lipid metabolism, decrease of total cho-
lesterol, triglyceride and atherogenic index. The levels of 
glycosylated hemoglobin, C-peptide, insulin resistance 
index and systemic inflammation achieved within a 
month, are preserved as well. The results indicate that 
administration of metformin in patients suffering from type 
2 diabetes and coronary heart disease within 3 months is 
an effective and safe treatment for these patients [20]. 
Thus, the signal transduction of nuclear transcription 
factor κB is a critical point, in which the main inflamma-
tory, metabolic and regulatory pathways involved in the 
development of chronic inflammation are intercrossed. It 
is subject to correction of the preconditioning state of 
regulatory systems, especially in the presence of poly-
morphic variants of genes encoding key enzymes, recep-
tors and regulatory proteins [10, 11]. 
The obtained results will contribute to the formation of 
a systematic approach to the development and use of 
new technologies for prevention and effective pharmaco-
genetic treatment of diseases based on chronic inflam-
mation. 
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